胶囊内视镜市场按产品类型、内视镜模式、年龄层、应用、分销管道和最终用户划分－2025-2030 年全球预测

胶囊内视镜市场预计将在 2024 年达到 5.0212 亿美元，复合年增长率为 8.01%，到 2025 年将达到 5.4109 亿美元，到 2030 年将达到 7.9739 亿美元。

主要市场统计数据
基准年2024年	5.0212亿美元
预计2025年	5.4109亿美元
预测年份 2030	7.9739亿美元
复合年增长率（%）	8.01%

探索胶囊内视镜技术在重新定义非侵入性胃肠诊断和改善患者预后的变革作用

胶囊内视镜代表了胃肠道诊断领域的突破性创新，它用一种只需吞服的设备取代了传统的侵入性内视镜操作。胶囊内视镜配备高解析度影像感测器，外观隐蔽，为临床医生提供了前所未有的途径，能够深入观察小肠深处先前难以观察到的区域。因此，与传统内视镜相比，患者的不适感和风险更低，有望提高需要定期接受胃肠检查的患者的遵从率。

确定影响胶囊内视镜领域并推动全球胃肠成像创新的关键技术和监管变化

突破性的技术进步在胶囊内视镜领域取得了前所未有的变革，模糊了诊断与数据主导决策之间的界线。近期推出的超高解析度成像晶片带来了前所未有的清晰度，使得以前难以察觉的细微黏膜病变得以检测。同时，电源管理技术的进步延长了胶囊的电池寿命，使其能够延长胃肠道的传输时间，并实现从食道到结肠的全面可视化。

评估2025年美国关税调整对全球胶囊内视镜供应链和市场动态的累积影响

2025年美国重新征收关税为胶囊内视镜供应链带来了新的挑战，促使相关人员重新评估筹资策略和成本结构。先前依赖从主要製造地进口零件的设备製造商，如今正面临专用影像感测器、微电池单元和无线传输模组关税上调的挑战。这导致製造成本上升，迫使製造商寻找替代供应商或建立策略伙伴关係关係，以缓解关税带来的价格上涨压力。

揭示产品变体、内视镜模式、年龄层、临床应用、分销管道和最终用户类别的关键细分洞察

全面的細項分析揭示了不同产品组合和临床环境如何影响市场成长的清晰模式。例如，大肠胶囊内视镜系统因其针对大肠评估的专门设计而备受青睐，而食道和小肠平台则针对特定的诊断场景。每个产品层级都展现出独特的性能特征，从针对食道转运优化的胶囊尺寸到专为小肠成像设计的先进光学涂层。

重点介绍美洲、欧洲、中东和非洲以及亚太市场胶囊内视镜应用的区域动态和市场驱动因素

在美洲，尤其是北美市场，对胃肠道诊断基础设施的投资正在加速胶囊内视镜作为一种非侵入性检查方式的普及。优惠的报销政策和大肠直肠癌筛检计画的高普及率，促使临床医师将胶囊内视镜系统纳入常规诊疗方案。在拉丁美洲，不断增长的医疗预算和公共卫生措施正在推动胶囊内视镜的普及，儘管各国在成本考量和监管时间表方面存在差异。

在胶囊内视镜市场格局不断演变的背景下，与推动创新和策略合作的关键产业领导者会面

产业领导者以其技术力和策略伙伴关係关係旨在提升胶囊内视镜的临床效用。大型跨国公司正在大力投资高清影像增强和电池续航解决方案，并与研究机构合作，在同行评审研究中检验其贡献。这些合作伙伴关係使得即时资料传输和整合立体定位感测器等设计功能的快速迭代成为可能，从而提高了手术效率和诊断准确性。

为行业领导者提供切实可行的建议，以提高技术部署的营运效率；监管合规性和市场定位策略

产业领导者应优先将人工智慧功能整合到胶囊内视镜平台中，以提高病变检测的准确性并缩短解读时间。透过整合能够自动标记异常的机器学习演算法，製造商可以提供全面的诊断工作流程，从而减轻临床医生的负担并加快患者护理流程。同时，投资模组化设计原则和弹性製造可以帮助企业应对不断变化的法规环境，并最大限度地减少供应链漏洞。

概述用于捕捉行业趋势的调查方法；检验数据来源并对胶囊内视镜市场洞察进行彻底分析

该研究结合了同行评审期刊、监管申报资料和临床试验资料库的系统性综述，以及对顶尖胃肠病学家、设备工程师和采购专家的深入访谈。严格的资讯来源三角检定将定性见解与多个资料点进行交叉检验，增强了新兴趋势分析的可信度。二级资讯来源包括专业医学协会的白皮书和监管机构发布的指南，为评估核准时间表和上市后监管要求提供了框架。

胶囊内视镜在现代胃肠诊断中的演化整合和未来前景的总结性展望

随着胶囊内视镜技术的不断发展，其对胃肠诊断的变革性影响日益显着。从增强的超高解析度成像到远端医疗平台内的无缝数据集成，这些可吞服的设备正在重新定义临床医生的工作流程和患者体验。监管调整和合作研究倡议正在加速创新週期，推动从一次性胶囊到配备人工智慧和先进感测器的智慧系统的转变。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章市场动态

• 整合人工智慧演算法用于胶囊内视镜系统中的即时病变检测
• 可携式胶囊内视镜系统具有更长的电池寿命，可以延长小肠成像时间，而不会给患者带来不适
• 全肠胶囊内视镜的使用率正在不断提高，它可以全面观察从食道到大肠的消化道
• 开发可生物降解的胶囊内视镜，最大限度地减少回收需求并降低环境影响
• 将胶囊内视镜数据与远端医疗和云端分析平台相结合的远端患者监护解决方案的成长
• 具有高解析度成像能力以及 pH、压力和温度测量能力的多感测器胶囊的进展
• 透过胃肠病学家和设备製造商之间的合作，实现胶囊内视镜检查报告和解释通讯协定的标准化

第六章 市场洞察

• 波特五力分析
• PESTEL分析

第七章 2025年美国关税的累积影响

第 8 章：胶囊内视镜市场（依产品类型）

• 结肠胶囊内视镜检查
• 食道胶囊内视镜检查
• 小肠胶囊内视镜检查

第九章胶囊内视镜市场：内视镜模式

• 可重复使用的胶囊
• 免洗胶囊

第 10 章胶囊内视镜市场（依年龄层）

• 成人
• 老年人
• 孩子们

第11章胶囊内视镜市场的应用

• 乳糜泻
• 大肠癌筛检
• 克隆氏症
• 胃食道逆流症
• 不明原因消化道出血（OGIB）
• 小肠肿瘤
• 溃疡检测

第12章胶囊内视镜市场按分销管道

• 离线
• 在线的

第十三章胶囊内视镜市场（依最终用户）

• 门诊手术中心（ASC）
• 诊断中心
• 医院
• 研究所

第 14 章：美洲胶囊内视镜市场

• 美国
• 加拿大
• 墨西哥
• 巴西
• 阿根廷

15. 欧洲、中东和非洲胶囊内视镜市场

• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 阿拉伯聯合大公国
• 沙乌地阿拉伯
• 南非
• 丹麦
• 荷兰
• 卡达
• 芬兰
• 瑞典
• 奈及利亚
• 埃及
• 土耳其
• 以色列
• 挪威
• 波兰
• 瑞士

16. 亚太胶囊内视镜市场

• 中国
• 印度
• 日本
• 澳洲
• 韩国
• 印尼
• 泰国
• 菲律宾
• 马来西亚
• 新加坡
• 越南
• 台湾

第十七章竞争格局

• 2024年市场占有率分析
• 2024年FPNV定位矩阵
• 竞争分析
  • Advin Health Care
  • Anx Robotica Corp.
  • Beijing Richen-Force Science & Technology Co.,Ltd
  • Biocam Sp. z oo
  • CapsoVision, Inc.
  • Covestro AG
  • Duomed Group
  • Fujifilm Holding Corporation
  • Intromedic co., Ltd
  • JINSHAN Science & Technology（Group）Co., Ltd.
  • Medtronic PLC
  • MU Ltd.
  • Olympus Corporation
  • RF Systems Lab
  • Shangxian Minimal Invasive Inc
  • STERIS
  • SynMed Ltd.

第十八章 研究人工智慧

第十九章 研究统计

第二十章 研究联络人

第21章 研究报导

第22章 附录

The Capsule Endoscopy Market was valued at USD 502.12 million in 2024 and is projected to grow to USD 541.09 million in 2025, with a CAGR of 8.01%, reaching USD 797.39 million by 2030.

KEY MARKET STATISTICS
Base Year [2024]	USD 502.12 million
Estimated Year [2025]	USD 541.09 million
Forecast Year [2030]	USD 797.39 million
CAGR (%)	8.01%

Exploring the Transformative Role of Capsule Endoscopy Technologies in Redefining Noninvasive Gastrointestinal Diagnostics for Enhanced Patient Outcomes

Capsule endoscopy represents a landmark innovation in gastrointestinal diagnostics by replacing traditional invasive endoscopic procedures with a single swallowable device. The discreet nature of the capsule, equipped with high-definition imaging sensors, offers clinicians unrivaled access to deep sections of the small intestine that were previously challenging to visualize. As a result, patients experience reduced discomfort and risk compared to conventional endoscopy, fostering higher compliance rates among individuals requiring regular gastrointestinal assessment.

Initial trials and subsequent clinical adoption have underscored the value of this technology in detecting a spectrum of conditions, ranging from obscure gastrointestinal bleeding to suspected small intestine tumors. Enhanced illumination systems and expanded battery life have significantly increased the diagnostic yield, allowing longer transit durations and continuous image capture throughout the digestive tract. Coupled with wireless data acquisition platforms, these improvements have streamlined workflow for medical teams while offering real-time insights into patient health.

Looking ahead, ongoing research is focused on integrating advanced analytics and artificial intelligence into the capsule endoscopy framework. By leveraging machine learning algorithms to flag potential anomalies and cross-reference patient histories, the next generation of capsule endoscopy promises both heightened accuracy and accelerated reporting. This evolution underscores the critical role of capsule endoscopy in shaping future standards for noninvasive gastrointestinal care

Identifying Major Technological and Regulatory Shifts Shaping the Capsule Endoscopy Landscape and Driving Innovation in Gastrointestinal Imaging Worldwide

Technological breakthroughs have catalyzed an unparalleled transformation in the capsule endoscopy landscape, blurring the lines between diagnostics and data-driven decision making. Recent introductions of ultra-high-resolution imaging chips have delivered unprecedented clarity, enabling the detection of minute mucosal lesions that would have previously gone unnoticed. Meanwhile, advancements in power management have extended capsule battery life, permitting extended transit through the gastrointestinal tract and ensuring comprehensive visualization from the esophagus to the colon.

Simultaneously, regulatory frameworks have evolved to accommodate the growing complexity of ingestible diagnostic devices. Medical agencies across key markets have introduced expedited pathways for novel capsule designs and enhanced post-market surveillance protocols. These regulatory shifts have encouraged manufacturers to innovate aggressively while maintaining rigorous safety and efficacy standards. Consequently, the market has witnessed a surge in clinical collaborations aimed at validating new imaging modalities, including optical coherence tomography and hyperspectral analysis, within a capsule format.

In parallel, the convergence of telemedicine platforms and remote patient monitoring tools has redefined the patient experience. Physicians can now review capsule imagery in real time, and patients benefit from streamlined pre-procedure instructions and post-procedure consultations without in-person visits. These transformative shifts underscore an industry moving rapidly toward integrated care models, where capsule endoscopy functions not only as a diagnostic instrument but also as a key element in a broader digital health ecosystem

Evaluating the Cumulative Effects of the 2025 United States Tariff Adjustments on Global Capsule Endoscopy Supply Chains and Market Dynamics

In 2025, the imposition of updated United States tariffs has introduced a new set of challenges for the capsule endoscopy supply chain, prompting stakeholders to reevaluate sourcing strategies and cost structures. Historically reliant on components imported from major manufacturing hubs, device producers are now navigating elevated duties on specialized imaging sensors, microbattery units, and wireless transmission modules. As a result, production costs have risen, compelling manufacturers to explore alternative suppliers and form strategic partnerships to mitigate tariff-induced price pressures.

Moreover, these tariff adjustments have created ripple effects across distribution networks, with importers and healthcare providers facing higher acquisition expenses. Many hospitals and diagnostic centers have responded by renegotiating procurement agreements and seeking volume-based pricing arrangements to preserve budgetary margins. In tandem, suppliers are investing in domestic assembly capabilities and localized manufacturing initiatives to offset the financial impact of cross-border trade barriers. These activities have fostered greater supply chain resilience and have accelerated the implementation of nearshore production models.

Looking forward, industry participants are also advocating for policy dialogues to balance trade objectives with healthcare affordability. While tariffs aim to bolster domestic industrial growth, the ultimate concern remains the accessibility and pricing of life-saving diagnostic technologies. Stakeholders are therefore engaging with policymakers and trade associations to ensure that tariff frameworks evolve in a manner that sustains innovation while protecting patient access to advanced gastrointestinal diagnostics

Unveiling Critical Segmentation Insights for Product Variants Endoscopy Modes Age Groups Clinical Applications Distribution Channels and End User Categories

An in-depth segmentation analysis reveals distinct patterns in how different product configurations and clinical contexts shape market uptake. For instance, colon capsule endoscopy systems have gained prominence due to their targeted design for colorectal evaluation, while esophageal and small bowel platforms address specialized diagnostic scenarios. Each product tier demonstrates unique performance attributes, from capsule dimensions optimized for esophageal transit to advanced optical coatings engineered for small-bowel imaging.

Equally important is the differentiation by endoscopy mode, where reusable capsules are preferred for high-volume diagnostic centers seeking cost efficiencies, and single-use models appeal to institutions prioritizing sterility and patient safety. Age demographics further refine this picture, with adult patients representing the core user base, geriatric cohorts demanding minimally invasive options due to comorbidities, and pediatric applications driving innovation in capsule miniaturization.

Clinical applications present another layer of granularity, as the technology is employed for celiac disease monitoring, colon cancer screening, Crohn's disease assessment, gastroesophageal reflux evaluation, obscure gastrointestinal bleeding investigation, small intestine tumor detection, and precise ulcer identification. Distribution channels vary from established offline networks encompassing medical device distributors to emerging online portals that facilitate direct procurement. Finally, end users span ambulatory surgical centers seeking streamlined workflows, diagnostic centers focused on outpatient throughput, hospitals integrating capsule endoscopy into broader GI service lines, and research institutes exploring next-generation functionalities

Highlighting Regional Dynamics and Growth Drivers for Capsule Endoscopy Adoption across the Americas Europe Middle East Africa and Asia Pacific Markets

Across the Americas, particularly in North American markets, investment in gastrointestinal diagnostic infrastructure has accelerated the adoption of capsule endoscopy as a preferred noninvasive option. Favorable reimbursement policies and a high prevalence of colorectal cancer screening programs have driven clinicians to incorporate capsule systems into routine protocols. In Latin America, growing healthcare budgets and public health initiatives are fostering incremental uptake, although cost considerations and regulatory timelines vary by country.

Within Europe, the Middle East and Africa region, heterogeneous reimbursement landscapes pose both opportunities and challenges. Western European nations benefit from well-established reimbursement codes and robust clinical guidelines, which have enabled consistent integration of capsule endoscopy into gastroenterology practices. Conversely, parts of the Middle East are characterized by rapid modernization of healthcare facilities, leading to significant adoption surges in urban centers, while certain African markets remain constrained by limited specialist availability and infrastructure gaps.

The Asia-Pacific market exhibits dynamic growth driven by expanding healthcare access and rising awareness of digestive health issues. Countries such as Japan and South Korea, with advanced manufacturing capabilities and supportive regulatory frameworks, continue to lead in capsule endoscopy innovation. Meanwhile, emerging economies in Southeast Asia and India are witnessing increased demand for cost-effective, noninvasive diagnostic modalities, fueled by public screening campaigns and telemedicine integration. These regional dynamics underscore the importance of tailored market entry and engagement strategies

Showcasing Key Industry Leaders Driving Innovation and Strategic Collaborations in the Evolving Capsule Endoscopy Market Landscape

Industry leaders have distinguished themselves through a blend of technological prowess and strategic partnerships aimed at advancing the clinical utility of capsule endoscopy. Major multinational corporations have invested heavily in high-definition imaging enhancements and extended battery solutions, collaborating with research institutions to validate their contributions in peer-reviewed studies. These alliances have enabled rapid iteration of design features, such as real-time data transmission and integrated localization sensors, which enhance procedural efficiency and diagnostic accuracy.

Mid-tier manufacturers have likewise carved out specialized niches by focusing on cost-effective capsule platforms optimized for specific clinical segments, including pediatric applications and outpatient screening programs. These companies often leverage modular production frameworks to respond swiftly to evolving regulatory requirements and customer feedback. Collaborative agreements with hospitals and diagnostic clinics have facilitated field trials, enabling iterative refinement of software algorithms that support lesion detection and report generation.

In addition to hardware innovation, several key players have formed ecosystem partnerships with telehealth providers and cloud service operators to deliver end-to-end diagnostic solutions. This trend underscores a shift toward value-based care models, where capsule endoscopy emerges as a central component of integrated gastrointestinal health management. Collectively, these strategic activities reflect a competitive landscape where agility, clinical validation, and cross-sector collaborations define market leadership

Actionable Recommendations for Industry Leaders to Enhance Technological Adoption Operational Efficiency Regulatory Compliance and Market Positioning Strategies

Industry leaders should prioritize the integration of artificial intelligence capabilities into their capsule endoscopy platforms to enhance lesion detection accuracy and reduce interpretation times. By embedding machine learning algorithms capable of automated anomaly flagging, manufacturers can offer comprehensive diagnostic workflows that alleviate clinician burden and expedite patient care pathways. In parallel, investment in modular design principles and flexible manufacturing arrangements will help companies navigate evolving regulatory environments and minimize supply chain vulnerabilities.

Strategic partnerships with both domestic and nearshore component suppliers can mitigate the financial impact of cross-border tariffs while supporting more resilient production networks. Engaging proactively with regulatory agencies to secure expedited review pathways will further accelerate time-to-market for next-generation systems. In terms of market expansion, targeting emerging regions through customized reimbursement models and training programs can unlock new user bases, particularly in underserved areas where gastrointestinal conditions impose significant healthcare burdens.

Finally, healthcare providers and device developers alike should cultivate collaborative networks with telemedicine and digital health service providers. Offering integrated diagnostic packages that combine capsule endoscopy with remote patient monitoring and virtual follow-up consultations will align with broader value-based care initiatives. These actionable strategies will empower stakeholders to optimize diagnostic performance, reinforce market positioning, and deliver superior patient outcomes

Outlining the Research Methodology Employed to Capture Industry Trends Validate Data Sources and Ensure Thorough Analysis of Capsule Endoscopy Market Insights

This research effort combined a systematic review of peer-reviewed journals, regulatory filings, and clinical trial databases with in-depth interviews conducted with leading gastroenterologists, device engineers, and procurement specialists. Rigorous source triangulation ensured that qualitative insights were cross-validated against multiple data points, enhancing the reliability of emerging trend analysis. Secondary sources included white papers from professional medical societies and guidelines published by regulatory agencies, which provided a framework for assessing approval timelines and post-market surveillance requirements.

Primary research involved structured discussions with senior clinicians who have pioneered capsule endoscopy adoption in diverse clinical settings, alongside conversations with technical experts responsible for device design and integration. Feedback from procurement teams across ambulatory centers and hospitals shed light on distribution channel dynamics and purchasing decision criteria. All insights were synthesized through a multi-stage analytical process, which encompassed thematic coding to identify core drivers, barriers, and innovation hotspots. These findings were then subjected to peer review by an experienced advisory panel to ensure comprehensive coverage and unbiased interpretation. Through this methodology, the study delivers a robust and nuanced understanding of the capsule endoscopy ecosystem

Drawing Conclusive Perspectives on the Evolution Integration and Future Outlook of Capsule Endoscopy in Modern Gastrointestinal Diagnostics

As capsule endoscopy technologies continue to evolve, their transformative impact on gastrointestinal diagnostics is becoming increasingly evident. From ultra-high-resolution imaging enhancements to seamless data integration within telehealth platforms, these ingestible devices are redefining clinician workflows and patient experiences alike. Regulatory adaptations and collaborative research initiatives have accelerated innovation cycles, driving the transition from single-use capsules toward intelligent systems powered by artificial intelligence and advanced sensor modalities.

The cumulative effect of U.S. tariff adjustments in 2025 highlights the importance of resilient supply chain strategies and nearshore manufacturing capabilities. Meanwhile, segmentation analysis underscores distinct preferences among clinical applications, age groups, and endoscopy modes, offering manufacturers opportunities to tailor solutions to specific market niches. Regional dynamics in the Americas, EMEA, and Asia-Pacific further illustrate the necessity of localized approaches that consider reimbursement landscapes, infrastructure maturity, and patient awareness levels.

Looking ahead, stakeholders who embrace modular design, foster strategic ecosystem partnerships, and prioritize regulatory alignment will be best positioned to capture the next wave of growth. The evolution of capsule endoscopy is not simply a technological journey, but a paradigm shift toward patient-centric, data-driven healthcare. As this field matures, it will play an integral role in holistic gastrointestinal care pathways, empowering clinicians with tools that deliver precision, efficiency, and enhanced patient outcomes

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

• 4.1. Introduction
• 4.2. Market Sizing & Forecasting

5. Market Dynamics

• 5.1. Integration of artificial intelligence algorithms for real-time lesion detection in capsule endoscopy systems
• 5.2. Portable capsule endoscopy systems with enhanced battery life enabling extended small bowel imaging sessions without patient discomfort
• 5.3. Emerging adoption of pan-intestinal capsule scopes for comprehensive GI tract visualization from esophagus to colon
• 5.4. Development of biodegradable capsule endoscopes minimizing retrieval requirements and reducing environmental impact
• 5.5. Growth in remote patient monitoring solutions integrating capsule endoscopy data with telehealth and cloud analytics platforms
• 5.6. Advances in multi-sensor capsules offering pH pressure and temperature measurements alongside high resolution imaging capabilities
• 5.7. Collaboration between gastroenterologists and device manufacturers to standardize capsule endoscopy reporting and interpretation protocols

6. Market Insights

• 6.1. Porter's Five Forces Analysis
• 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Capsule Endoscopy Market, by Product Type

• 8.1. Introduction
• 8.2. Colon Capsule Endoscopy
• 8.3. Esophageal Capsule Endoscopy
• 8.4. Small Bowel Capsule Endoscopy

9. Capsule Endoscopy Market, by Endoscopy Mode

• 9.1. Introduction
• 9.2. Reusable Capsules
• 9.3. Single Use Capsules

10. Capsule Endoscopy Market, by Age Group

• 10.1. Introduction
• 10.2. Adult
• 10.3. Geriatric
• 10.4. Pediatric

11. Capsule Endoscopy Market, by Application

• 11.1. Introduction
• 11.2. Celiac Disease
• 11.3. Colon Cancer Screening
• 11.4. Crohn's Disease
• 11.5. Gastroesophageal Reflux Disease
• 11.6. Obscure Gastrointestinal Bleeding (OGIB)
• 11.7. Small Intestine Tumors
• 11.8. Ulcer Detection

12. Capsule Endoscopy Market, by Distribution Channel

• 12.1. Introduction
• 12.2. Offline
• 12.3. Online

13. Capsule Endoscopy Market, by End User

• 13.1. Introduction
• 13.2. Ambulatory Surgical Centers (ASCs)
• 13.3. Diagnostic Centers
• 13.4. Hospitals
• 13.5. Research Institutes

14. Americas Capsule Endoscopy Market

• 14.1. Introduction
• 14.2. United States
• 14.3. Canada
• 14.4. Mexico
• 14.5. Brazil
• 14.6. Argentina

15. Europe, Middle East & Africa Capsule Endoscopy Market

• 15.1. Introduction
• 15.2. United Kingdom
• 15.3. Germany
• 15.4. France
• 15.5. Russia
• 15.6. Italy
• 15.7. Spain
• 15.8. United Arab Emirates
• 15.9. Saudi Arabia
• 15.10. South Africa
• 15.11. Denmark
• 15.12. Netherlands
• 15.13. Qatar
• 15.14. Finland
• 15.15. Sweden
• 15.16. Nigeria
• 15.17. Egypt
• 15.18. Turkey
• 15.19. Israel
• 15.20. Norway
• 15.21. Poland
• 15.22. Switzerland

16. Asia-Pacific Capsule Endoscopy Market

• 16.1. Introduction
• 16.2. China
• 16.3. India
• 16.4. Japan
• 16.5. Australia
• 16.6. South Korea
• 16.7. Indonesia
• 16.8. Thailand
• 16.9. Philippines
• 16.10. Malaysia
• 16.11. Singapore
• 16.12. Vietnam
• 16.13. Taiwan

17. Competitive Landscape

• 17.1. Market Share Analysis, 2024
• 17.2. FPNV Positioning Matrix, 2024
• 17.3. Competitive Analysis
  • 17.3.1. Advin Health Care
  • 17.3.2. Anx Robotica Corp.
  • 17.3.3. Beijing Richen-Force Science & Technology Co.,Ltd
  • 17.3.4. Biocam Sp. z o.o.
  • 17.3.5. CapsoVision, Inc.
  • 17.3.6. Covestro AG
  • 17.3.7. Duomed Group
  • 17.3.8. Fujifilm Holding Corporation
  • 17.3.9. Intromedic co., Ltd
  • 17.3.10. JINSHAN Science & Technology (Group) Co., Ltd.
  • 17.3.11. Medtronic PLC
  • 17.3.12. MU Ltd.
  • 17.3.13. Olympus Corporation
  • 17.3.14. RF Systems Lab
  • 17.3.15. Shangxian Minimal Invasive Inc
  • 17.3.16. STERIS
  • 17.3.17. SynMed Ltd.

18. ResearchAI

19. ResearchStatistics

20. ResearchContacts

21. ResearchArticles

22. Appendix